Company Filing History:

12 out of 3,222

Genentech, Inc.

patents

1 out of 204

University of Vermont and State Agricultural College

where one patent can have more than one assignee

Years Active: 1993-2008

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7427596 - Variants of vascular endothelial cell growth factor, their uses, and processes for their production (2008-09-23),

2. 7005505 - Variants of vascular endothelial cell growth factor (2006-02-28),

3. 6750044 - Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids (2004-06-15),

4. 6057428 - Variants of vascular endothelial cell growth factor (2000-05-02),

5. 6020473 - Nucleic acids encoding variants of vascular endothelial cell growth (2000-02-01),

6. 5945432 - Thrombolytic agents and thienopyridine derivatives in acute stroke (1999-08-31),

7. 5612029 - Tissue plasminogen activator glycosylation variants with improved (1997-03-18),

8. 5520911 - Variants of plasminogen activators and processes for their production (1996-05-28),

9. 5385732 - Variants of tissue plasminogen activator, compositions and methods of (1995-01-31),

10. 5346824 - DNA encoding variants of tissue plasminogen activators and expression (1994-09-13),

11. 5338546 - Tissue plasminogen activator variants with decreased clearance (1994-08-16),

12. 5270198 - DNA molecules encoding variants of tissue plasminogen activators, (1993-12-14),

13. 5246850 - DNA molecules encoding human tissue plasminogen activator variants with (1993-09-21),

Title: The Innovative Contributions of Bruce A. Keyt

Introduction

Bruce A. Keyt, an accomplished inventor based in Pacifica, CA, has made notable strides in the field of biomedical innovations. With a solid portfolio comprising 13 patents, he has established himself as a significant contributor to advancements in vascular biology.

Latest Patents

Among his latest innovations, Keyt has developed two pivotal patents focusing on variants of vascular endothelial cell growth factor (VEGF). The inventions entail the preparation of VEGF variants that provide selective binding characteristics to the kinase domain region (KDR) and the FMS-like tyrosine-kinase region (FLT-1). These variants modify the binding characteristics to enhance biological properties of the VEGF molecule. This work is essential for advancing therapeutic strategies targeting vascular endothelial growth factors.

Career Highlights

Keyt's career is marked by contributions to prestigious organizations. He has worked with Genentech, Inc., renowned for its cutting-edge biopharmaceutical developments, and the University of Vermont and State Agricultural College, where he has likely collaborated on various research initiatives aimed at innovative biological research.

Collaborations

Throughout his career, Bruce A. Keyt has collaborated with distinguished professionals such as Francis Hung Nguyen and Napoleone Ferrara. These partnerships have fostered an environment of innovation and excellence in their shared pursuits within vascular biology and related fields.

Conclusion

In summary, Bruce A. Keyt stands out as a prolific inventor whose work in the realm of vascular endothelial growth factors has the potential to influence therapeutic techniques significantly. With his continued dedication to innovation and collaboration, Keyt's future endeavors promise to yield transformative advancements in biomedical science.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

For the Inventor, By the Inventor

Bruce A Keyt

Company Filing History:

Years Active: 1993-2008